Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis

Shinji Kawano, Kazuaki Matsumoto, Ryohei Hara, Yuko Kuroda, Kazuro Ikawa, Norifumi Morikawa, Tetsuya Horino, Seiji Hori, Junko Kizu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V<inf>1</inf>, 1.27±0.38h<sup>-1</sup> for K<inf>12</inf>, 0.71±0.40h<sup>-1</sup> for K<inf>21</inf> and 0.17±0.02h<sup>-1</sup> for K<inf>10</inf>. Based on these mean parameters (V<inf>1</inf>, K<inf>12</inf>, K<inf>21</inf> and K<inf>10</inf>), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40% T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40% T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40% T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.

Original languageEnglish
Pages (from-to)476-478
Number of pages3
JournalJournal of Infection and Chemotherapy
Volume21
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

meropenem
Renal Dialysis
Pharmacokinetics
Japan
Critical Illness

Keywords

  • Continuous venovenous hemodialysis
  • Dosing regimen
  • Meropenem
  • Pharmacokinetics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis. / Kawano, Shinji; Matsumoto, Kazuaki; Hara, Ryohei; Kuroda, Yuko; Ikawa, Kazuro; Morikawa, Norifumi; Horino, Tetsuya; Hori, Seiji; Kizu, Junko.

In: Journal of Infection and Chemotherapy, Vol. 21, No. 6, 01.06.2015, p. 476-478.

Research output: Contribution to journalArticle

Kawano, Shinji ; Matsumoto, Kazuaki ; Hara, Ryohei ; Kuroda, Yuko ; Ikawa, Kazuro ; Morikawa, Norifumi ; Horino, Tetsuya ; Hori, Seiji ; Kizu, Junko. / Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis. In: Journal of Infection and Chemotherapy. 2015 ; Vol. 21, No. 6. pp. 476-478.
@article{87914db409384dc1acf542facb080d67,
title = "Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis",
abstract = "The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V1, 1.27±0.38h-1 for K12, 0.71±0.40h-1 for K21 and 0.17±0.02h-1 for K10. Based on these mean parameters (V1, K12, K21 and K10), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40{\%} T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40{\%} T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40{\%} T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.",
keywords = "Continuous venovenous hemodialysis, Dosing regimen, Meropenem, Pharmacokinetics",
author = "Shinji Kawano and Kazuaki Matsumoto and Ryohei Hara and Yuko Kuroda and Kazuro Ikawa and Norifumi Morikawa and Tetsuya Horino and Seiji Hori and Junko Kizu",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jiac.2015.02.011",
language = "English",
volume = "21",
pages = "476--478",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis

AU - Kawano, Shinji

AU - Matsumoto, Kazuaki

AU - Hara, Ryohei

AU - Kuroda, Yuko

AU - Ikawa, Kazuro

AU - Morikawa, Norifumi

AU - Horino, Tetsuya

AU - Hori, Seiji

AU - Kizu, Junko

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V1, 1.27±0.38h-1 for K12, 0.71±0.40h-1 for K21 and 0.17±0.02h-1 for K10. Based on these mean parameters (V1, K12, K21 and K10), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40% T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40% T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40% T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.

AB - The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V1, 1.27±0.38h-1 for K12, 0.71±0.40h-1 for K21 and 0.17±0.02h-1 for K10. Based on these mean parameters (V1, K12, K21 and K10), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40% T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40% T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40% T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.

KW - Continuous venovenous hemodialysis

KW - Dosing regimen

KW - Meropenem

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84937761730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937761730&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2015.02.011

DO - 10.1016/j.jiac.2015.02.011

M3 - Article

VL - 21

SP - 476

EP - 478

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 6

ER -